Gilead Sciences (NASDAQ:GILD) Given "Buy (B)" Rating at Weiss Ratings

Gilead Sciences (NASDAQ:GILD - Get Free Report)'s stock had its "buy (b)" rating restated by analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

A number of other research analysts have also recently issued reports on GILD. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research note on Friday, July 25th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a "sector perform" rating in a research note on Wednesday. UBS Group boosted their target price on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research note on Friday, August 8th. Daiwa America raised shares of Gilead Sciences from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, August 19th. Finally, Citigroup boosted their target price on shares of Gilead Sciences from $125.00 to $135.00 and gave the company a "buy" rating in a report on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $117.67.

Gilead Sciences Trading Up 1.3%

Shares of GILD stock opened at $118.25 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. Gilead Sciences has a 12-month low of $84.17 and a 12-month high of $121.83. The firm has a 50 day moving average price of $114.48 and a two-hundred day moving average price of $110.12. The company has a market capitalization of $146.73 billion, a PE ratio of 23.56, a price-to-earnings-growth ratio of 0.79 and a beta of 0.34.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to the consensus estimate of $6.95 billion. During the same period in the previous year, the business earned $2.01 earnings per share. The firm's quarterly revenue was up 1.4% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. As a group, analysts predict that Gilead Sciences will post 7.95 earnings per share for the current year.

Insiders Place Their Bets

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the company's stock in a transaction dated Monday, September 29th. The shares were sold at an average price of $111.66, for a total value of $1,116,600.00. Following the completion of the sale, the chief executive officer directly owned 591,203 shares of the company's stock, valued at approximately $66,013,726.98. This represents a 1.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $283,925.00. Following the transaction, the chief financial officer directly owned 159,555 shares of the company's stock, valued at $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 82,000 shares of company stock valued at $9,402,130. Corporate insiders own 0.27% of the company's stock.

Institutional Trading of Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of GILD. Smallwood Wealth Investment Management LLC purchased a new stake in Gilead Sciences in the 1st quarter worth approximately $25,000. Activest Wealth Management raised its position in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares during the period. GoalVest Advisory LLC increased its position in shares of Gilead Sciences by 7,566.7% in the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 227 shares during the period. Harbor Asset Planning Inc. purchased a new position in shares of Gilead Sciences in the second quarter valued at about $27,000. Finally, Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences in the first quarter valued at about $29,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.